Adaptive Biotechnologies Corp (ADPT): Cash & Equivalents
$70.50M
As of 2025-12-31
$169.87M
As of 2026-06-30
-7.8%
3-year compound annual growth
-10.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.50M | +47.1% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $47.92M | -26.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $65.06M | -27.7% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $90.03M | -35.3% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $139.06M | +12.7% | 2023-02-14, Balance as of period end |
| 2020-12-31 | $123.44M | +27.8% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $96.58M | +75.5% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $55.03M | n/a | 2020-02-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $70.50M | +47.1% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $163.08M | +41.0% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $183.05M | -19.1% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $496.30M | +43.9% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $91.14M | -36.7% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $167.20M | -70.2% |
Compare ADPT, VCEL, IOVA, TWST side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗